• Something wrong with this record ?

HPV testing as an effective triage strategy in the follow-up after fertility-sparing treatment for glandular lesions of the uterine cervix

L. Dostalek, P. Freitag, M. Slovackova, T. Zima, M. Komarc, L. Fricova, T. Fucik, K. Nemejcova, D. Cibula, D. Brynda, J. Slama

Language English Country England, Great Britain

Document type Journal Article

E-resources Online Full text

NLK ProQuest Central from 2018-01-01 to 6 months ago
Health & Medicine (ProQuest) from 2018-01-01 to 6 months ago

OBJECTIVE: The management and surveillance of glandular pre-cancerous lesions of the uterine cervix present distinct challenges compared with squamous lesions, primarily attributed to the lower effectiveness of diagnostic methods such as cytology or colposcopy. This study aimed to investigate the long-term safety of fertility-sparing treatment for adenocarcinoma in situ and microinvasive adenocarcinoma of the cervix, while identifying factors associated with recurrence, with a particular emphasis on the role of human papillomavirus (HPV) testing. METHODS: We retrospectively reviewed data from all patients with histopathologically confirmed adenocarcinoma in situ or microinvasive cervical adenocarcinoma who received treatment at a single center between 2002 and 2023. The study involved the examination of consecutive surgical specimens and the follow-up details. Factors associated with recurrence were assessed in a subgroup of patients with available long-term follow-up data (at least 6 months). RESULTS: In total, 143 patients (112 with adenocarcinoma in situ and 31 with adenocarcinoma) were included in the analysis. Among the 86 patients who underwent fertility-sparing treatment, the recurrence rate was 9% (12% for adenocarcinoma in situ and 4% for adenocarcinoma) during a median follow-up period of 56.6 months (range 7-179). No patients who were HPV negative experienced recurrence during the follow-up period. In contrast, among patients who were HPV positive, the recurrence rate was 38%. Additionally, HPV 16/18 positivity displayed a notable association with a higher risk of recurrence compared with the other high-risk genotypes, although this difference did not reach statistical significance (83% vs 10%; p=0.083, log-rank). CONCLUSION: Our retrospective study demonstrated a significant association between the risk of recurrence and HPV status during the follow-up period. Consequently, long-term follow-up utilizing HPV testing and genotyping appears to be a secure alternative to a hysterectomy.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24020011
003      
CZ-PrNML
005      
20241024110924.0
007      
ta
008      
241015s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1136/ijgc-2023-004920 $2 doi
035    __
$a (PubMed)38054269
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Dostalek, Lukas $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000301514559
245    10
$a HPV testing as an effective triage strategy in the follow-up after fertility-sparing treatment for glandular lesions of the uterine cervix / $c L. Dostalek, P. Freitag, M. Slovackova, T. Zima, M. Komarc, L. Fricova, T. Fucik, K. Nemejcova, D. Cibula, D. Brynda, J. Slama
520    9_
$a OBJECTIVE: The management and surveillance of glandular pre-cancerous lesions of the uterine cervix present distinct challenges compared with squamous lesions, primarily attributed to the lower effectiveness of diagnostic methods such as cytology or colposcopy. This study aimed to investigate the long-term safety of fertility-sparing treatment for adenocarcinoma in situ and microinvasive adenocarcinoma of the cervix, while identifying factors associated with recurrence, with a particular emphasis on the role of human papillomavirus (HPV) testing. METHODS: We retrospectively reviewed data from all patients with histopathologically confirmed adenocarcinoma in situ or microinvasive cervical adenocarcinoma who received treatment at a single center between 2002 and 2023. The study involved the examination of consecutive surgical specimens and the follow-up details. Factors associated with recurrence were assessed in a subgroup of patients with available long-term follow-up data (at least 6 months). RESULTS: In total, 143 patients (112 with adenocarcinoma in situ and 31 with adenocarcinoma) were included in the analysis. Among the 86 patients who underwent fertility-sparing treatment, the recurrence rate was 9% (12% for adenocarcinoma in situ and 4% for adenocarcinoma) during a median follow-up period of 56.6 months (range 7-179). No patients who were HPV negative experienced recurrence during the follow-up period. In contrast, among patients who were HPV positive, the recurrence rate was 38%. Additionally, HPV 16/18 positivity displayed a notable association with a higher risk of recurrence compared with the other high-risk genotypes, although this difference did not reach statistical significance (83% vs 10%; p=0.083, log-rank). CONCLUSION: Our retrospective study demonstrated a significant association between the risk of recurrence and HPV status during the follow-up period. Consequently, long-term follow-up utilizing HPV testing and genotyping appears to be a secure alternative to a hysterectomy.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a dospělí $7 D000328
650    12
$a nádory děložního čípku $x virologie $x patologie $x diagnóza $x terapie $7 D002583
650    12
$a infekce papilomavirem $x diagnóza $x virologie $7 D030361
650    _2
$a lidé středního věku $7 D008875
650    _2
$a lokální recidiva nádoru $7 D009364
650    _2
$a zachování plodnosti $x metody $7 D059247
650    _2
$a adenokarcinom $x virologie $x patologie $7 D000230
650    _2
$a třídění pacientů $x metody $7 D014218
650    _2
$a následné studie $7 D005500
650    _2
$a Papillomaviridae $x izolace a purifikace $7 D027383
655    _2
$a časopisecké články $7 D016428
700    1_
$a Freitag, Pavel $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Slovackova, Miroslava $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Zima, Tomas $u Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Komarc, Martin $u Institute of Biophysics and Informatics, First Faculty of Medicine of Charles University in Prague, Prague, Czech Republic
700    1_
$a Fricova, Lenka $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Fucik, Tomas $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Nemejcova, Kristyna $u Department of Pathology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Cibula, David $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Brynda, Daniel $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic
700    1_
$a Slama, Jiri $u Department of Obstetrics, Gynecology and Neonatology, First Faculty of Medicine of Charles University in Prague and General University Hospital, Prague, Czech Republic Jiri.Slama@vfn.cz
773    0_
$w MED00009896 $t International journal of gynecological cancer : official journal of the International Gynecological Cancer Society $x 1525-1438 $g Roč. 34, č. 2 (2024), s. 216-223
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38054269 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024110918 $b ABA008
999    __
$a ok $b bmc $g 2202320 $s 1231984
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 34 $c 2 $d 216-223 $e 20240205 $i 1525-1438 $m International journal of gynecological cancer : official journal of the International Gynecological Cancer Society $n Int J Gynecol Cancer $x MED00009896
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...